Drug Discovery
AmideBio is a preclinical stage biotechnology company pursuing therapeutics that target metabolic disease.
AmideBio’s lead program is the development of novel glucose responsive insulins (GRIs) that will eliminate the need for basal and prandial insulins through a single weekly dose. These novel GRIs do not require complex chemical modifications and respond in real-time to blood glucose levels to improve glycemic control and could virtually eliminate hypoglycemic events in the full realization of the GRI concept.
AmideBio is also developing a solution-stable, long-acting glucagon for for the treatment of congenital hyperinsulinism, an orphan indication.
AmideBio’s single chain insulin (SCI) analogs are resistant to thermal and chemical degradation at elevated temperature. The company is currently seeking a partner to further develop these SCI analogs.
These programs benefit from a strong IP position and know-how in the rapid manufacturing of ultrapure peptides and proteins.